Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience

D. Zapletalova, N. André, L. Deak, M. Kyr, V. Bajciova, P. Mudry, L. Dubska, R. Demlova, Z. Pavelka, K. Zitterbart, J. Skotakova, K. Husek, A. Martincekova, P. Mazanek, T. Kepak, M. Doubek, L. Kutnikova, D. Valik, J. Sterba

. 2012 ; 82 (5) : 249-260.

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12034545
E-zdroje Online Plný text

NLK ProQuest Central od 1998-01-01 do 2015-11-30
Medline Complete (EBSCOhost) od 1998-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1998-01-01 do 2015-11-30
Health & Medicine (ProQuest) od 1998-01-01 do 2015-11-30
Family Health Database (ProQuest) od 1998-01-01 do 2015-11-30
Public Health Database (ProQuest) od 1998-01-01 do 2015-11-30

Odkazy

PubMed 22538363
DOI 10.1159/000336483
Knihovny.cz E-zdroje

BACKGROUND: The outcome of children with refractory/relapsed malignancies remains poor and novel therapies are urgently required. One of the promising approaches is metronomic chemotherapy. We present the clinical results of 74 children with advanced solid tumors treated according to treatment recommendation with data registry in three European pediatric centers. METHODS: COMBAT (Combined Oral Metronomic Biodifferentiating Antiangiogenic Treatment) included low-dose daily temozolomide, etoposide, celecoxib, vitamin D, fenofibrate and retinoic acid. From 2004 to 2010, 74 children were enrolled. RESULTS: The 2-year overall survival (OS) was 43.1% (median 15.4, range 1.3-69.9 months). Of the 74 patients, 50 patients (68%) died and 24 are alive: 6 (8%) with progressive disease, 7 (9%) with stable disease/partial response and 11 (15%) in complete response. Median time to response was 6 months. Of 62 patients with initially measurable disease, 25 (40%) had radiological response or stable disease. Fourteen of 25 showing clinical benefit responded within the first 6 months. The treatment was well tolerated on an outpatient basis. Regarding non-hematological toxicity of grade ≥2, hepatotoxicity of grade 3 occurred in 8 children and grade 3 cheilitis in 16 children. CONCLUSION: COMBAT is a feasible and effective treatment option for patients with relapsing/refractory malignancies. The treatment is well tolerated with a low acute toxicity profile.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12034545
003      
CZ-PrNML
005      
20240618124220.0
007      
ta
008      
121023s2012 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000336483 $2 doi
035    __
$a (PubMed)22538363
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Zapletalová, Danica $7 xx0232988 $u Department of Pediatric Oncology, University Hospital Brno, School of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience / $c D. Zapletalova, N. André, L. Deak, M. Kyr, V. Bajciova, P. Mudry, L. Dubska, R. Demlova, Z. Pavelka, K. Zitterbart, J. Skotakova, K. Husek, A. Martincekova, P. Mazanek, T. Kepak, M. Doubek, L. Kutnikova, D. Valik, J. Sterba
520    9_
$a BACKGROUND: The outcome of children with refractory/relapsed malignancies remains poor and novel therapies are urgently required. One of the promising approaches is metronomic chemotherapy. We present the clinical results of 74 children with advanced solid tumors treated according to treatment recommendation with data registry in three European pediatric centers. METHODS: COMBAT (Combined Oral Metronomic Biodifferentiating Antiangiogenic Treatment) included low-dose daily temozolomide, etoposide, celecoxib, vitamin D, fenofibrate and retinoic acid. From 2004 to 2010, 74 children were enrolled. RESULTS: The 2-year overall survival (OS) was 43.1% (median 15.4, range 1.3-69.9 months). Of the 74 patients, 50 patients (68%) died and 24 are alive: 6 (8%) with progressive disease, 7 (9%) with stable disease/partial response and 11 (15%) in complete response. Median time to response was 6 months. Of 62 patients with initially measurable disease, 25 (40%) had radiological response or stable disease. Fourteen of 25 showing clinical benefit responded within the first 6 months. The treatment was well tolerated on an outpatient basis. Regarding non-hematological toxicity of grade ≥2, hepatotoxicity of grade 3 occurred in 8 children and grade 3 cheilitis in 16 children. CONCLUSION: COMBAT is a feasible and effective treatment option for patients with relapsing/refractory malignancies. The treatment is well tolerated with a low acute toxicity profile.
650    _2
$a metronomické podávání léků $7 D059250
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a inhibitory angiogeneze $x aplikace a dávkování $7 D020533
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $7 D000971
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a dakarbazin $x aplikace a dávkování $x analogy a deriváty $7 D003606
650    _2
$a etoposid $x aplikace a dávkování $7 D005047
650    _2
$a studie proveditelnosti $7 D005240
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fenofibrát $x aplikace a dávkování $7 D011345
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a isotretinoin $x aplikace a dávkování $7 D015474
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nádory $x farmakoterapie $7 D009369
650    _2
$a pyrazoly $x aplikace a dávkování $7 D011720
650    _2
$a registrace $7 D012042
650    _2
$a sulfonamidy $x aplikace a dávkování $7 D013449
650    _2
$a vitamin D $x aplikace a dávkování $7 D014807
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a André, N. $u Metronomics Global Health Initiative, and iService d'Hématologie et Oncologie Pédiatrique, Hôpital pour Enfants de La Timone AP-HM, Marseille, France $7 gn_A_00006367
700    1_
$a Deák, L. $7 xx0318591 $u Department of Pediatric Oncology, University Hospital Košice, Košice, Slovak Republic
700    1_
$a Kýr, Michal $7 mub2014808498 $u Departments of aPediatric Oncology, University Hospital Brno, School of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Bajčiová, Viera $7 xx0089689 $u Department of Pediatric Oncology, University Hospital Brno, School of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Múdry, Peter $7 xx0153990 $u Department of Pediatric Oncology, University Hospital Brno, School of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Dubska, L. $u Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Demlová, Regina $7 xx0063726 $u Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Pavelka, Zdeněk $7 xx0093082 $u Department of Pediatric Oncology, University Hospital Brno, School of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Zitterbart, Karel $7 xx0142630 $u Department of Pediatric Oncology, University Hospital Brno, School of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Skotáková, Jarmila, $d 1957- $7 mzk2004237308 $u Department of Pediatric Radiology, University Hospital Brno, School of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Hušek, Karel $7 xx0077500 $u Department of Pathology, University Hospital Brno, School of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Martinčeková, Alexandra. $7 xx0239279 $u Department of Pediatric Oncology, University Hospital Brno, School of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Mazánek, Pavel $7 xx0143064 $u Department of Pediatric Oncology, University Hospital Brno, School of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kepák, Tomáš $7 xx0081397 $u Department of Pediatric Oncology, University Hospital Brno, School of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Doubek, Michael, $d 1972- $7 mzk2004217554 $u Department of Internal Medicine-Hematology, University Hospital Brno, School of Medicine, and eCentral European Institute of Technology, Masaryk University
700    1_
$a Kutnikova, L. $u Department of Pediatric Oncology, University Hospital Brno, School of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Valík, Dalibor $7 xx0061177 $u Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Štěrba, Jaroslav, $d 1962- $7 mzk2004237310 $u Department of Pediatric Oncology, University Hospital Brno, School of Medicine, Masaryk University, Brno, Czech Republic; Metronomics Global Health Initiative, Hôpital pour Enfants de La Timone AP-HM, Marseille, France
773    0_
$w MED00003601 $t Oncology $x 1423-0232 $g Roč. 82, č. 5 (2012), s. 249-260
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22538363 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20121023 $b ABA008
991    __
$a 20240618124221 $b ABA008
999    __
$a ok $b bmc $g 956555 $s 792042
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 82 $c 5 $d 249-260 $i 1423-0232 $m Oncology $n Oncology $x MED00003601
LZP    __
$b NLK122 $a Pubmed-20121023
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace